MedicalResearch.com Interview with:
Daniel Reker, PhD
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
MedicalResearch.com: What is the background for this study?
Response: We started thinking more about this topic following a clinical experience five years ago that Dr. Traverso was involved in where a patient suffering form Celiac disease received a prescription of a drug which potentially had gluten. This experience really opened our eyes for how little we knew about the inactive ingredients and how clinical workflows do not currently accommodate for such scenarios.
We therefore set up a large scale analysis to better understand the complexity of the inactive ingredient portion in a medication as well as how frequently critical ingredients are included that could potential affect sensitive patients.